The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 75.00
Bid: 70.00
Ask: 80.00
Change: -2.50 (-3.23%)
Spread: 10.00 (14.286%)
Open: 77.50
High: 77.50
Low: 75.00
Prev. Close: 77.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

31 Oct 2019 07:00

RNS Number : 7070R
Biome Technologies PLC
31 October 2019
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

 

31 October 2019

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides a trading update for the nine months ended 30 September 2019.

 

Bioplastics Division

 

Revenues in the Bioplastics division in Q3 were £0.9m, representing the best quarter of 2019 to date and a 50% increase on the prior year comparative (Q3 2018: £0.6m). The division's revenues in the first nine months of the financial year stand at £2.3m (2018: £1.5m), 21% higher than the full year 2018 revenues of £1.9m.

 

Revenues in Q3 reflected strong underlying demand for products that have been commercialised for some time (e.g. outer packaging and non-woven filter mesh for the US coffee pod market) coupled with continuing revenues in materials for both cutlery and a single serve nutrition pod that are in the early stages of their market deployment.

 

The Bioplastics team continues to work on a strong product development pipeline of opportunities with a variety of existing and new customers. Encouragingly, the final testing for a heat stable and compostable material for coffee pod rings has now been completed and commercial revenues are expected to commence in Q4.

 

The division's medium-term Industrial Biotechnology research continues, with two of its government grant backed projects having been completed at the end of the quarter, which has delivered a number of important technical results and initial techno-economic assessments to guide future work. Key focuses in this area continue to be the development and testing of several novel bio-based and biodegradable polymers and their supporting bio-based monomers.

 

Stanelco RF Technologies Division

 

Revenues in the RF Technologies division in Q3 were £0.6m (Q3 2018: £2.0m), resulting in revenues in the first nine months of the financial year of £2.8m (2018: £5.5m), as the division returns to a more normalised turnover level from the previously reported exceptionally high levels of 2018.

 

The Board continues to expect full year revenues for this division to be in line with those achieved in 2017, with the final quarter underpinned by a multiple furnace order for delivery in Q4, as reported in previous announcements.

 

Group Performance

 

Total Group revenues in Q3 were £1.5m (2018: £2.6m), taking Group revenues for the nine months to 30 September 2019 to £5.1m (2018: £7.0m), with the Bioplastics division's revenues at £2.3m, already above those of full year 2018.

 

The Group's cash position as at 30 September 2019 was £0.6m (30 June 2019: £1.7m). In Q3, the principal utilisers of cash were the RF division, as it was building the multiple furnaces for delivery in Q4, and the Bioplastics division, as it increased its working capital utilisation in line with its anticipated trading performance going forward. The Group year end cash position is anticipated to be in line with current market expectations.

 

The Group announced in September that it had raised £1.3m (£1.2m net of costs) to support the increased working capital requirements of the Bioplastics division's growth. Shareholder approval was obtained on 30 September and the funds were received in early October.

 

Group Outlook

 

The Group has continued its upward momentum in the Bioplastics division and the fund raise of £1.2m (net) that completed in early Q4 will support both existing business positions and a more vigorous approach to this fast growing market. Trading conditions for the RF division remain as expected. It is against this backdrop that the Board expects the full year results to be in line with current market expectations.

 

- Ends -

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

In 2018, the Board has adopted the following three high level KPIs for the next three years to continue its ambitious momentum:

·; Compound revenue growth of 25% per annum across the Group and 40% compound revenue growth in the Bioplastics division

·; Diversify the Group's turnover by product and market to ensure that no one product or end customer contributes more than 15% of revenues by 2020

·; Increase investment in the Group's next generation of products by spending significantly more per annum on average than the £0.3m per annum average spend over the previous strategic objective cycle

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastics.com 

www.stanelcorftechnologies.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFDIFUSFUSEIS
Date   Source Headline
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.